Explore Currently Enrolling Genentech and Roche Clinical Trials in Oncology

Search for clinical trials by making selections below.

Tumor Type View All

Breast Gastrointestinal Genitourinary Gynecologic Hematology Lung Melanoma Solid Tumor

Phase

III II I

Molecule*

Select...
Antibody-drug conjugate (RG7986) Anti-MUC16 TDC (RG7882) Anti-TIGIT MAb (MTIG7192A, RG6058) Atezolizumab (anti-PDL1 MAb) (RG7446) BET inhibitor (TEN-010, RG6146) CD20 TCB (RG6026) CD20 TDB (RG7828) CEA TCB (RG7802) Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ChK1 inhibitor (GDC-0575, RG7741) Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) Codrituzumab (anti–glypican-3 MAb) (GC33, RG7686) Emactuzumab (anti–CSF-1R MAb) (RG7155) FAP-DR5 biMAb (RG7386) FAP-IL2v FP (RG7461) Glypican-3/CD3 biMAb (CHU) Idasanutlin (MDM2 antagonist) (RG7388) Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) Monoclonal antibody (RG6160) Obinutuzumab Other Pan-RAF inhibitor (RG6185) Personalized cancer vaccine (RG6180) PI3K inhibitor (GDC-0077, RG6114) Polatuzumab vedotin (anti-CD79b ADC) (RG7596) Raf/MEK dual inh Selective estrogen receptor degrader (SERD[2]) (GDC-0927/SRN-927, RG6047) Selicrelumab (anti-CD40 MAb) (RG7876) Taselisib (PI3K inhibitor) (GDC-0032, RG7604) Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601)

US Region

International

Region

Select...
Clear All
View Results
Expand +

Tumor Type: xxx

Phase: xxx

Region: xxx

Molecule: xxx

For more information about recruiting clinical trials, please call the Trial Information Support Line for US Clinical Trial information at 888-662-6728 or visit ClinicalTrials.gov.
Email your search results to yourself.
Clear All
View Results
Tumor Type Phase Molecule* Location Study Contact
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) AR NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) AR
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) AZ NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) AZ
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CH NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CH
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) DE NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) DE
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) DK NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) DK
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) ES NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) ES
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FL NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FL
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FR NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FR
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) GB NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) GB
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) IT NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) IT
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) MA NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) MA
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) NL NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) NL
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) PA NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) PA
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) TX NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Solid Tumor II, I Atezolizumab (anti-PDL1 MAb) (RG7446) TX
NCT02541604—A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AR NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AR
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AZ NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AZ
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CA NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CA
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CA NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CA
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) DE NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) DE
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) ES NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) ES
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) FL NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) FL
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) FR NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) FR
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) GB NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) GB
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) IL NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) IL
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) IT NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) IT
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) MA NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) MA
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) NY NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) NY
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) PA NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) PA
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) TX NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) TX
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) CO NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) CO
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) CT NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) CT
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) DK NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) DK
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) ES NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) ES
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) FR NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) FR
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) IT NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) IT
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) MA NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) MA
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) NL NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) NL
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) SC NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) SC
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) TN NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) TN
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) TX NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB, Atezolizumab (anti-PDL1 MAb) (RG7446) TX
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-OX40 MAb (MOXR0916, RG7888), Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02410512—A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Anti-OX40 MAb (MOXR0916, RG7888), Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02410512—A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-OX40 MAb (MOXR0916, RG7888), Atezolizumab (anti-PDL1 MAb) (RG7446) ES NCT02410512—A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Anti-OX40 MAb (MOXR0916, RG7888), Atezolizumab (anti-PDL1 MAb) (RG7446) ES
NCT02410512—A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) AR NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) AR
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) AU NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) AU
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CO NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CO
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CT NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CT
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) ES NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) ES
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) FR NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) FR
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) KR NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) KR
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) MA NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) MA
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) MD NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) MD
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) TN NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) TN
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) CO NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) CO
NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) CT NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) CT
NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) DC NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) DC
NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) KR NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) KR
NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) MN NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) MN
NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) NC NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) NC
NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) NY NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) NY
NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) TN NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) TN
NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) TW NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Capecitabine, Paclitaxel, Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) TW
NCT02715531—A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Obinutuzumab AZ NCT02174172—A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Obinutuzumab AZ
NCT02174172—A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Obinutuzumab CA NCT02174172—A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Obinutuzumab CA
NCT02174172—A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Obinutuzumab CT NCT02174172—A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Obinutuzumab CT
NCT02174172—A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Obinutuzumab NC NCT02174172—A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Obinutuzumab NC
NCT02174172—A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Obinutuzumab NL NCT02174172—A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Obinutuzumab NL
NCT02174172—A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Obinutuzumab TN NCT02174172—A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, Obinutuzumab TN
NCT02174172—A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) CT NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) CT
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) DK NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) DK
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ES NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ES
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) NL NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) NL
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) NY NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) NY
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) BE NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) BE
NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) CT NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) CT
NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) ES NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) ES
NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) FR NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) FR
NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) MA NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) MA
NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) NY NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) NY
NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) CA NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) CA
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) DK NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) DK
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) ES NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) ES
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) FR NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) FR
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) NL NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) NL
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) BE NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) BE
NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) ES NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) ES
NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) FR NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) FR
NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) BE NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) BE
NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) FR NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) FR
NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) NY NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) NY
NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I FAP-IL2v FP (RG7461) AZ NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors
Solid Tumor I FAP-IL2v FP (RG7461) AZ
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I FAP-IL2v FP (RG7461) CO NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors
Solid Tumor I FAP-IL2v FP (RG7461) CO
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I FAP-IL2v FP (RG7461) DK NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors
Solid Tumor I FAP-IL2v FP (RG7461) DK
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I FAP-IL2v FP (RG7461) ES NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors
Solid Tumor I FAP-IL2v FP (RG7461) ES
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I FAP-IL2v FP (RG7461) GB NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors
Solid Tumor I FAP-IL2v FP (RG7461) GB
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I FAP-IL2v FP (RG7461) NL NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors
Solid Tumor I FAP-IL2v FP (RG7461) NL
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) CA NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) CA
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) ES NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) ES
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) MA NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) MA
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) NY NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) NY
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) TN NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) TN
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) AZ NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) AZ
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) ES NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) ES
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) FL NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) FL
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) IL NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) IL
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MO NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MO
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) NY NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) NY
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) OK NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) OK
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TN NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TN
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TX NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TX
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) CA NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) CA
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) DK NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) DK
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) ES NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) ES
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Vemurafenib AU NCT01767623—A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients
Solid Tumor I Vemurafenib AU
NCT01767623—A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients
Tumor
Type
Phase Molecule* Location
Solid Tumor I Vemurafenib IL NCT01767623—A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients
Solid Tumor I Vemurafenib IL
NCT01767623—A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients
Tumor
Type
Phase Molecule* Location
Solid Tumor I Vemurafenib TR NCT01767623—A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients
Solid Tumor I Vemurafenib TR
NCT01767623—A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients
1 of 132 clinical trials
1-4 of 132 clinical trials
ClickTap on the NCT numbers above to visit ClinicalTrials.gov for further details about each trial, including eligibility criteria, primary and secondary outcome measures, and contacts and locations.
This website is intended for US healthcare professionals and contains information on investigational compounds and drug uses that have not been approved by the FDA. Click "OK" if you are a healthcare professional and wish to proceed.
CancelOK
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
CancelContinue
Results contain non-US trial information only.

Click "OK" if you wish to proceed.
CancelOK